Welcome to our dedicated page for Meiragtx Holdings news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings stock.
MeiraGTx Holdings plc develops clinical-stage genetic medicines for diseases with high unmet need, with recurring updates centered on AAV gene therapy programs, ocular disease, radiation-induced xerostomia, and regulated gene-expression technology. Company news includes clinical disclosures for AAV-hAQP1 and AAV2-hAQP1 in grade 2/3 radiation-induced xerostomia, ophthalmology programs such as AAV-AIPL1 for Leber congenital amaurosis 4, and the acquired bota-vec program for X-linked retinitis pigmentosa.
Updates also cover strategic collaborations and license agreements, in-house manufacturing capabilities for genetic medicines, riboswitch platform development, operating results, financing arrangements, shareholder voting matters, and capital-structure disclosures tied to MGTX ordinary shares.
MeiraGTx Holdings plc (MGTX) reported its Q1 2022 financial results, revealing a license revenue increase to $5.6 million, up from $4.6 million in Q1 2021, mainly due to Janssen collaborations. R&D expenses rose to $23.1 million, reflecting growth in clinical trial costs. The net loss attributable to shareholders was $31 million, compared to $23.6 million a year prior. The company continues to progress its Phase 3 Lumeos trial for X-linked Retinitis Pigmentosa and recently completed the AQUAx study for radiation-induced xerostomia. MeiraGTx maintains a cash reserve of approximately $114 million.
MeiraGTx Holdings announced new clinical data from its Phase 1/2 trial of botaretigene sparoparvovec aimed at treating X-linked Retinitis Pigmentosa (XLRP) at the ARVO 2022 Annual Meeting. Results suggest localized improvements in retinal sensitivity up to 12 months post-treatment. The data indicates that the gene therapy could restore photoreceptor function, with results extending beyond the delivery site. MeiraGTx collaborates with Janssen Pharmaceuticals on this gene therapy, further demonstrating progress in developing treatments for inherited retinal diseases.
MeiraGTx Holdings (NASDAQ:MGTX) has appointed Dr. Debra Yu to its Board of Directors. Dr. Yu brings over 30 years of healthcare experience, previously serving as President and Chief Strategy Officer of LianBio. Her background includes senior positions in business development at Pfizer and venture capital firms. CEO Alexandria Forbes highlighted that Dr. Yu's expertise will provide valuable insights as MeiraGTx, a gene therapy company, continues to expand its operations and product pipeline focusing on ocular, neurodegenerative diseases, and xerostomia.
MeiraGTx Holdings plc (NASDAQ:MGTX) announced participation in several key conferences. Alexandria Forbes, Ph.D. will present at:
- Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022
- Mass General Brigham World Medical Innovation Forum on May 4, 2022
- BofA Securities 2022 Healthcare Conference on May 10, 2022
- 2022 RBC Capital Markets Global Healthcare Conference on May 18, 2022
Webcasts will be available on the company's Investor page.
MeiraGTx Holdings plc (MGTX) reported key advancements in its clinical pipeline, including the initiation of Phase 3 trials for botaretigene sparoparvovec in collaboration with Janssen Pharmaceuticals, resulting in a $30 million milestone payment. The company also shared positive preliminary results from the Phase 1 AQUAx trial for AAV-hAQP1, aimed at treating radiation-induced xerostomia, where 6 of 7 patients showed symptom improvement. As of December 31, 2021, MeiraGTx had cash reserves of $137.7 million, ensuring operational funding through mid-2023. However, net losses increased to $79.6 million.
MeiraGTx has announced the receipt of a $30 million milestone payment from Janssen Pharmaceuticals for achieving a clinical milestone in the Phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy targeting X-linked retinitis pigmentosa (XLRP). The trial is now actively dosing patients, and the company is also eligible for additional milestone payments related to other gene therapy programs in collaboration with Janssen. XLRP is a severe retinal disease, and this therapy aims to improve vision outcomes for patients.
On December 15, 2021, MeiraGTx Holdings plc (NASDAQ: MGTX) will conduct a virtual R&D Day showcasing its innovative gene regulation platforms. The event, led by CEO Alexandria Forbes, will cover topics such as promoter engineering and synthetic riboswitch technology. Participants can register for the event online and access a live webcast, with a replay available on the company's investor page. MeiraGTx aims to transform gene therapy with its proprietary platforms that promise precise gene expression control, targeting ocular, neurodegenerative diseases, and xerostomia.
MeiraGTx Holdings (MGTX) reported promising preliminary data from its Phase 1 AQUAx trial of AAV-hAQP1, aimed at treating grade 2/3 radiation-induced xerostomia (RIX). The results indicate that 6 out of 7 participants showed clinically meaningful improvement in xerostomia symptoms at 90 days. One participant maintained improvement at 24 months. AAV-hAQP1 demonstrated good safety and tolerability. The company plans to initiate a Phase 2 study in late 2022. RIX affects about 170,000 patients in the U.S., revealing a significant unmet medical need.
MeiraGTx Holdings plc (NASDAQ: MGTX) announced a conference call on December 7, 2021, to discuss updates on its Phase 1 AQUAx clinical trial targeting radiation-induced xerostomia. Additionally, a virtual R&D Day will occur on December 15, 2021, focusing on their gene regulation platforms. The AQUAx trial evaluates AAV-hAQP1's safety and its efficacy in improving salivary output in patients post-radiation therapy. The company is pioneering riboswitch gene regulation technology, aiming to address unmet medical needs across multiple areas, including ocular and neurodegenerative diseases.
MeiraGTx Holdings plc (Nasdaq: MGTX) reported its Q3 2021 financial results, revealing a license revenue of $6.9 million, up from $5.1 million in Q3 2020. The net loss for the quarter was $25.9 million, or $0.59 per share, compared to a loss of $6.4 million last year. The company is progressing its Phase 3 Lumeos Trial and the AQUAx Phase 1 study, while also presenting advancements in its riboswitch gene regulation platform. Despite increased R&D expenses of $21.6 million, MeiraGTx has $143.6 million in cash, sufficient for operations into Q2 2023.